Business
MEI Pharma Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In MEI Pharma, Inc. To Contact The Firm
New York, New York--(Newsfile Corp. - September 25, 2020) -  Faruqi & Faruqi, LLP, a ...
About this update from Lithos Group Ltd
[{"type":"text","content":"MEI Pharma Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In MEI Pharma, Inc. To Contact The FirmNew York, New York--(Newsfile Corp. - September 25, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in MEI Pharma, Inc. (\"MEI Pharma\" or the \"Company\") (NASDAQ:MEIP) of the October 9, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in MEI Pharma stock or options between August 2, 2017 and July 1, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/MEIP. There is no cost or obligation to you.You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected]. CONTACT:FARUQI & FARUQI, LLP685 Third Avenue, 26th FloorNew York, NY 10017Attn: Richard Gonnello, [email protected]: (877) 247-4292 or (212) 983-9330The lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of all those who purchased MEI Pharma securities between August 2, 2017 and July 1, 2020 (the \"Class Period\"). The case, Bahat v. Mei Pharma, Inc. et al., No. 20-cv-01543 was filed on August 10, 2020, and has been assigned to Judge William Q. Hayes.The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) MEI Pharma had overstated Pracinostat's potential efficacy as an AML treatment for the target population; (2) consequently, the Phase 3 Pracinostat Trial was unlikely to meet its primary endpoint of overall survival; (3) all the foregoing, once revealed, was foreseeably likely to have a material negative impact on the Company's financial condition and prospects for Pracinostat; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.Specifically, on July 2, 2020, during pre-market hours, MEI Pharma issued a press release announcing that it was discontinuing the Phase 3 Pracinostat Trial. The Company advised that an interim futility analysis of the Phase 3 Pracinostat Trial, undertaken by the study's Independent Data Monitoring Committ...